[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA26961A1 - Agonistes selectifs des recepteurs ep4 pour le traitement de l'osteoporose - Google Patents

Agonistes selectifs des recepteurs ep4 pour le traitement de l'osteoporose

Info

Publication number
MA26961A1
MA26961A1 MA27159A MA27159A MA26961A1 MA 26961 A1 MA26961 A1 MA 26961A1 MA 27159 A MA27159 A MA 27159A MA 27159 A MA27159 A MA 27159A MA 26961 A1 MA26961 A1 MA 26961A1
Authority
MA
Morocco
Prior art keywords
bone
loss
receptors
osteoporosis
relates
Prior art date
Application number
MA27159A
Other languages
English (en)
Inventor
Kimberly O'keefe Cameron
Bruce Allen Lefker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26961A1 publication Critical patent/MA26961A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DEPOSANT Société dite: PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 27 Novembre 2000 60/253,275 Voir en annexe le titre de l'invention et le texte de l'abrégé Agonistes sélectifs des récepteurs EP4 pour le traitement de 1'ostéoporose L'invention concerne des agonistes de prostaglandines sélectives des récepteurs EP4, de formule (I), dans laquelle R2, X, Z et Q répondent aux définitions figurant dans le présent mémoire. La présente invention concerne également des compositions pharmaceutiques contenant ces composés. La présente invention concerne également des méthodes de traitement d'affections qui comportent une faible masse osseuse, en particulier 1'ostéoporose, la fragilité, une fracture ostéoporotique, un défaut osseux, la perte de tissu osseux idiopathique de l'enfant, une perte d'os alvéolaire, une perte d'os mandibulaire, une fracture d'un os, une ostéotomie, une perte de tissu osseux associée à la périodontite ou une incarnation prostétique, chez un mammifère, comprenant l'administration de ces composés.
MA27159A 2000-11-27 2003-05-13 Agonistes selectifs des recepteurs ep4 pour le traitement de l'osteoporose MA26961A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25327500P 2000-11-27 2000-11-27

Publications (1)

Publication Number Publication Date
MA26961A1 true MA26961A1 (fr) 2004-12-20

Family

ID=22959588

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27159A MA26961A1 (fr) 2000-11-27 2003-05-13 Agonistes selectifs des recepteurs ep4 pour le traitement de l'osteoporose

Country Status (41)

Country Link
US (3) US6552067B2 (fr)
EP (1) EP1339678B1 (fr)
JP (2) JP3984164B2 (fr)
KR (1) KR20030053063A (fr)
CN (1) CN1476429A (fr)
AR (1) AR035074A1 (fr)
AT (1) ATE374182T1 (fr)
AU (1) AU2002210848A1 (fr)
BG (1) BG107697A (fr)
BR (1) BR0115687A (fr)
CA (1) CA2429850C (fr)
CY (1) CY1106976T1 (fr)
CZ (1) CZ20031257A3 (fr)
DE (1) DE60130675T2 (fr)
DK (1) DK1339678T3 (fr)
EA (1) EA200300379A1 (fr)
EC (1) ECSP034623A (fr)
EE (1) EE200300246A (fr)
ES (1) ES2291361T3 (fr)
GT (2) GT200100238A (fr)
HN (1) HN2001000266A (fr)
HU (1) HUP0400807A2 (fr)
IL (1) IL155368A0 (fr)
IS (1) IS6775A (fr)
MA (1) MA26961A1 (fr)
MX (1) MXPA03004623A (fr)
NO (1) NO20032360L (fr)
NZ (1) NZ525164A (fr)
OA (1) OA12533A (fr)
PA (1) PA8533901A1 (fr)
PE (1) PE20020637A1 (fr)
PL (1) PL362030A1 (fr)
PT (1) PT1339678E (fr)
SI (1) SI1339678T1 (fr)
SK (1) SK5562003A3 (fr)
SV (1) SV2003000746A (fr)
TN (1) TNSN01166A1 (fr)
TW (1) TW200424170A (fr)
UY (1) UY27038A1 (fr)
WO (1) WO2002042268A2 (fr)
ZA (1) ZA200302803B (fr)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE374182T1 (de) * 2000-11-27 2007-10-15 Pfizer Prod Inc Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose
BR0211201A (pt) * 2001-07-16 2004-07-13 Hoffmann La Roche Composto, processo para a preparação desse composto, sua utilização, composição farmacêutica que compreende o mesmo e método para o tratamento de uma enfermidade em um mamìfero
AU2002328338C1 (en) * 2001-07-16 2009-01-08 Ono Pharmaceutical Co., Ltd 2 pyrrolidone derivatives as prostanoid agonists
NZ530885A (en) 2001-07-23 2007-09-28 Ono Pharmaceutical Co Remedies for diseases with bone mass loss having EP4 agonist as the active ingredient
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
US7402605B2 (en) 2002-03-05 2008-07-22 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
AU2003209571A1 (en) * 2002-03-18 2003-09-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
DE60307607T2 (de) * 2002-03-18 2007-08-09 Pfizer Products Inc., Groton Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
WO2003103604A2 (fr) * 2002-06-01 2003-12-18 Applied Research Systems Ars Holding N.V Gamma lactames utilises en tant qu'agonistes de la prostaglandine et leur utilisation
US20050239872A1 (en) 2002-06-06 2005-10-27 Xavier Billot 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
US20060258726A1 (en) * 2002-06-06 2006-11-16 Xavier Billot 1,5-Disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
GB0219143D0 (en) * 2002-08-16 2002-09-25 Univ Leicester Modified tailed oligonucleotides
PT2465537T (pt) 2002-10-10 2016-08-03 Ono Pharmaceutical Co Microsferas compreendendo ono-1301
WO2004037813A1 (fr) * 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Derives de pyrrolidine-2-one en tant qu'agonistes du recepteur ep4
EP1581503A4 (fr) 2002-11-08 2007-07-25 Merck & Co Inc Compositions ophtalmiques pour traiter l'hypertension oculaire
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
BRPI0406717A (pt) * 2003-01-10 2005-12-20 Hoffmann La Roche Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção
US7256211B1 (en) * 2003-01-21 2007-08-14 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivatives and medical use thereof
ATE394372T1 (de) 2003-03-03 2008-05-15 Serono Lab G-lactamderivate als prostaglandinagonisten
US6734206B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6734201B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
AU2004261397A1 (en) 2003-07-18 2005-02-10 Laboratoires Serono Sa Hydrazide derivatives as prostaglandin receptors modulators
US7034051B2 (en) * 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
US7576122B2 (en) 2003-09-02 2009-08-18 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
CN102558231B (zh) 2003-09-04 2015-05-27 默沙东公司 用于治疗高眼压的眼用组合物
AU2004271978B2 (en) 2003-09-04 2009-02-05 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2005027931A1 (fr) * 2003-09-19 2005-03-31 Pfizer Products Inc. Compositions pharmaceutiques et methodes de traitement consistant en des associations d'un derive de la 2-alkylidene-19-nor-vitamine d et d'un agoniste selectif de ep2 ou ep4
EP1696893A1 (fr) * 2003-12-17 2006-09-06 Pfizer Products Incorporated Polytherapie continue avec des agonistes selctifs des recepteurs ep4 de la prostaglandine et un oestrogene pour le traitement de pathologies se manifestant par une faible masse osseuse
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
JP2008507521A (ja) 2004-07-20 2008-03-13 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症を治療するための眼科用組成物
US7858650B2 (en) 2004-10-22 2010-12-28 Ono Pharmaceutical Co., Ltd. Medicinal composition for inhalation
BRPI0518242A2 (pt) * 2004-10-26 2008-11-11 Allergan Inc mÉtodos terapÊuticos e de liberaÇço de agonistas de prostaglandina ep4
US7994195B2 (en) * 2004-11-04 2011-08-09 Allergan, Inc. Therapeutic substituted piperidone compounds
WO2006052893A2 (fr) 2004-11-08 2006-05-18 Allergan, Inc. Composes de pyrrolidone substitue therapeutique
US7101906B2 (en) * 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en) 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
WO2006080323A1 (fr) * 2005-01-27 2006-08-03 Asahi Kasei Pharma Corporation Composé hétérocyclique à six chaînons et utilisation de celui-ci
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
BRPI0611257A2 (pt) * 2005-05-06 2010-08-24 Allergan Inc beta-lactamas substituÍdas e uso em medicina do mesmo
US7772392B2 (en) 2005-05-06 2010-08-10 Allergan, Inc. Therapeutic substituted β-lactams
US7893107B2 (en) 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
KR100598678B1 (ko) * 2006-02-15 2006-07-19 (주)아이앤씨 수직형 대형 폐기물 파쇄기
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
WO2008073748A1 (fr) 2006-12-08 2008-06-19 University Of Rochester Expansion de cellules souches hématopoïétiques
BRPI0721067A2 (pt) 2006-12-18 2014-02-25 Allergan Inc Métodos e composições para tratar distúrbios gastrointestinais.
BRPI0811306A2 (pt) 2007-05-08 2015-01-27 Nat Univ Corp Hamamatsu Ativador de célula t citotóxica compreendendo agonista ep4
SI2155733T1 (sl) * 2007-05-23 2012-12-31 Allergan, Inc Ciklični laktami za zdravljenje glavkoma ali zvišanega očesnega tlaka
US8063033B2 (en) * 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US8202855B2 (en) 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
WO2010019796A1 (fr) * 2008-08-14 2010-02-18 Chemietek, Llc Dérivés d’amides hétérocycliques en tant qu’antagonistes du récepteur ep4
WO2010116270A1 (fr) 2009-04-10 2010-10-14 Pfizer Inc. Agonistes de ep2/4
WO2011047048A1 (fr) 2009-10-14 2011-04-21 Gemmus Pharma, Inc. Traitement par polythérapie pour infections virales
CN102917703B (zh) * 2010-03-08 2015-08-19 科研制药株式会社 新型ep4激动剂
CA2738045C (fr) 2010-05-28 2019-02-19 Simon Fraser University Composes conjugues, leurs procedes de fabrication et leurs utilisations
EP2397141A1 (fr) * 2010-06-16 2011-12-21 LEK Pharmaceuticals d.d. Procédé pour la synthèse d'acides aminés beta et leurs dérivés
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
AU2012217630A1 (en) 2011-02-17 2013-09-05 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013105997A2 (fr) 2011-02-23 2013-07-18 Allergan, Inc. Compositions et procédés de remplacement de tissu mou améliorés
WO2013123274A1 (fr) 2012-02-16 2013-08-22 Allergan, Inc. Compositions et procédés perfectionnés de remplacement de tissu mou
WO2013123275A1 (fr) 2012-02-16 2013-08-22 Allergan, Inc. Compositions et procédés perfectionnés de remplacement de tissu mou
EP2814510A1 (fr) 2012-02-16 2014-12-24 Allergan, Inc. Compositions et procédés perfectionnés de remplacement de tissu mou
EP2814482A1 (fr) 2012-02-16 2014-12-24 Allergan, Inc. Compositions et procédés perfectionnés de remplacement de tissu mou
ES2610428T3 (es) 2012-07-19 2017-04-27 Cayman Chemical Company, Incorporated Compuestos de difluorolactama como agonistas selectivos del receptor EP4 para su uso en el tratamiento de enfermedades y afecciones mediadas por EP4
EP2913047B1 (fr) 2012-10-29 2019-05-08 Cardio Incorporated Agent thérapeutique spécifique de maladie pulmonaire
CN105143217A (zh) 2013-03-15 2015-12-09 开曼化学股份有限公司 作为ep4受体选择性激动剂的内酰胺化合物用于治疗ep4介导的疾病和病症
JP6368351B2 (ja) 2013-03-15 2018-08-01 ケイマン ケミカル カンパニー， インコーポレーテッド ジフルオロラクタムアナログを合成する方法
WO2014144610A1 (fr) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Composés lactames en tant qu'agonistes sélectifs du récepteur ep4 pour l'utilisation dans le traitement de maladies et d'états à médiation par ep4
CN105392505A (zh) * 2013-07-19 2016-03-09 开曼化学股份有限公司 用于促进骨生长的方法、系统和组合物
US20160184387A1 (en) 2013-08-09 2016-06-30 Dominique Charmot Compounds and methods for inhibiting phosphate transport
WO2015056504A1 (fr) 2013-10-15 2015-04-23 小野薬品工業株式会社 Greffe d'endoprothèse à élution de médicament
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
TR201905436T4 (tr) 2014-06-06 2019-05-21 Allergan Inc Terapötik bileşikler olarak yeni ep4 agonistleri.
US9540357B1 (en) 2014-07-31 2017-01-10 Allergan, Inc. 15-aryl prostaglandins as EP4 agonists, and methods of use thereof
WO2016199111A1 (fr) 2015-06-12 2016-12-15 Simon Fraser University Composés agoniste d'ep4-bisphosphonate à liaison amide et leurs utilisations
CN107011377B (zh) * 2017-05-03 2019-02-26 南通书创药业科技有限公司 一种β-羰基磷酸酯的制备方法
CN111511736B (zh) 2017-12-25 2023-03-24 旭化成制药株式会社 含氮6元环化合物
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1158163A (en) 1966-06-15 1969-07-16 Berk Ltd Improvements in or relating to Polymer Compositions
ZA72645B (en) * 1971-03-05 1972-11-29 Upjohn Co Prostaglandin analogs
DE2346706A1 (de) * 1973-09-17 1975-04-03 Hoechst Ag Neue, nicht natuerlich vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung
US3975399A (en) 1974-08-06 1976-08-17 E. I. Du Pont De Nemours And Company 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
US4113873A (en) 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
NL7604330A (nl) 1975-04-28 1976-11-01 Syntex Inc Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten.
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en) 1976-03-31 1979-11-30 Labaz 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
CA1077948A (fr) * 1976-08-06 1980-05-20 Albin J. Nelson Production de 2-pyrrolidones disubstituees en 1,5
US4177346A (en) * 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
US4320136A (en) * 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
US4456613A (en) 1982-12-27 1984-06-26 E. I. Du Pont De Nemours And Company 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof
TW288010B (fr) 1992-03-05 1996-10-11 Pfizer
SE9302334D0 (sv) 1993-07-06 1993-07-06 Ab Astra New compounds
ZA944647B (en) 1993-07-06 1995-01-06 Astra Ab Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives
US5955481A (en) 1994-03-28 1999-09-21 Nissan Chemical Industries, Ltd. Pyridine type thiazolidines
TW420669B (en) 1994-03-28 2001-02-01 Nissan Chemical Ind Ltd Pyridine type thiazolidines
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
AU6427599A (en) * 1998-10-15 2000-05-01 Merck & Co., Inc. Methods for stimulating bone formation
JP2002527393A (ja) 1998-10-15 2002-08-27 メルク エンド カムパニー インコーポレーテッド 骨吸収阻害方法
WO2001046140A1 (fr) * 1999-12-22 2001-06-28 Pfizer Products Inc. Agonistes selectifs au recepteur ep4 dans le traitement de l'osteoporose
EP1132086B1 (fr) * 2000-01-31 2006-05-31 Pfizer Products Inc. Utilisation d'activateurs séléctifs du récepteur 4 (ep4) des prostaglandines pour traiter l'insuffisance renale chronique ou aigue
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
ATE374182T1 (de) * 2000-11-27 2007-10-15 Pfizer Prod Inc Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
IS6775A (is) 2003-04-10
SI1339678T1 (sl) 2007-12-31
JP2007197467A (ja) 2007-08-09
BG107697A (en) 2004-01-30
NO20032360L (no) 2003-07-23
BR0115687A (pt) 2003-09-09
CZ20031257A3 (cs) 2004-04-14
CY1106976T1 (el) 2012-09-26
CA2429850A1 (fr) 2002-05-30
PL362030A1 (en) 2004-10-18
TNSN01166A1 (fr) 2005-11-10
US7192979B2 (en) 2007-03-20
DE60130675T2 (de) 2008-01-24
DK1339678T3 (da) 2008-02-04
SK5562003A3 (en) 2004-08-03
ES2291361T3 (es) 2008-03-01
EA200300379A1 (ru) 2003-08-28
ATE374182T1 (de) 2007-10-15
PE20020637A1 (es) 2002-07-18
MXPA03004623A (es) 2003-09-05
EP1339678B1 (fr) 2007-09-26
JP3984164B2 (ja) 2007-10-03
HN2001000266A (es) 2002-01-30
PT1339678E (pt) 2007-11-30
EP1339678A2 (fr) 2003-09-03
US20030149086A1 (en) 2003-08-07
DE60130675D1 (de) 2007-11-08
NZ525164A (en) 2005-04-29
TW200424170A (en) 2004-11-16
AU2002210848A1 (en) 2002-06-03
ZA200302803B (en) 2004-04-13
PA8533901A1 (es) 2002-11-28
NO20032360D0 (no) 2003-05-26
US6747054B2 (en) 2004-06-08
SV2003000746A (es) 2003-01-13
HUP0400807A2 (hu) 2004-07-28
JP2004521869A (ja) 2004-07-22
CA2429850C (fr) 2008-12-30
US20040259921A1 (en) 2004-12-23
EE200300246A (et) 2003-10-15
AR035074A1 (es) 2004-04-14
KR20030053063A (ko) 2003-06-27
GT200100238AA (es) 2004-05-12
WO2002042268A3 (fr) 2002-07-25
OA12533A (en) 2006-06-05
GT200100238A (es) 2002-06-26
US20020065308A1 (en) 2002-05-30
US6552067B2 (en) 2003-04-22
IL155368A0 (en) 2003-11-23
WO2002042268A2 (fr) 2002-05-30
ECSP034623A (es) 2003-07-25
CN1476429A (zh) 2004-02-18
UY27038A1 (es) 2002-07-31

Similar Documents

Publication Publication Date Title
MA26961A1 (fr) Agonistes selectifs des recepteurs ep4 pour le traitement de l'osteoporose
AP2001002357A0 (en) EP4 receptor selective agonists in the treatment of osteoporosis.
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA27009A1 (fr) Derives de pyrazole pour le traitement d'une infection par le vih
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA27439A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
BR0110420A (pt) Agonistas muscarìnicos
ATE286500T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
TNSN07022A1 (fr) Derives de pyridine
CA2407100A1 (fr) 1-aroyle-piperidinyle benzamidines
MA30999B1 (fr) Composés.
MA30296B1 (fr) Nouvelles amines
MA34308B1 (fr) Triazolopyridines substituées
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
MA27017A1 (fr) Procede pour la production d'une composition pharmaceutique a faible dose ayant une distribution et activite medicamenteuses uniformes
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
MA30292B1 (fr) Amines primaires comme inhibiteurs de la renine
ATE386523T1 (de) Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
DE69919349D1 (de) Piperidinyl- und n-amidinopiperidinyl-derivate
MA27852A1 (fr) Derives de 1-(alkylaminoalkyl-pyrolidin-/piperidinyl)-2,2-diphenylacetamide utilises comme antagonistes du recepteur muscarinique
MA30924B1 (fr) Analogues de pyrazoles
IL149544A0 (en) N-ACYLPYRROLIDIN-2-YLALKYLBENZAMIDINE DERIVATIVES AS INHIBITORS OF FACTOR Xa
WO2002053099A3 (fr) Methodes et compositions de traitement d'une parodontopathie